Crispr Therapeutics Ag Stock Analysis

Crispr Stock Analysis Notes

About 71.0% of the company shares are held by institutions such as insurance companies. The book value of Crispr Therapeutics was currently reported as 24.56. The company recorded a loss per share of 2.7. Crispr Therapeutics had not issued any dividends in recent years. The entity had 333333:100 split on the 19th of July 2016. CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. CRISPR Therapeutics is traded on NASDAQ Exchange in the United States. For more info on Crispr Therapeutics AG please contact the company at 41 41 561 32 77 or go to https://www.crisprtx.com.

Crispr Therapeutics Investment Alerts

Crispr Therapeutics Upcoming and Recent Events

Crispr Largest EPS Surprises

View All Earnings Estimates

Crispr Therapeutics Environmental, Social, and Governance (ESG) Scores

Crispr Stock Institutional Investors

Note, although Crispr Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Crispr Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.65 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Crispr Therapeutics's market, we take the total number of its shares issued and multiply it by Crispr Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Crispr Profitablity

The company has Profit Margin (PM) of (0.8) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (278.94) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $278.94.

Management Efficiency

Crispr Therapeutics has return on total asset (ROA) of (0.0797) % which means that it has lost $0.0797 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1102) %, meaning that it created substantial loss on money invested by shareholders. Crispr Therapeutics' management efficiency ratios could be used to measure how well Crispr Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 05/23/2024, Return On Tangible Assets is likely to drop to -0.07. In addition to that, Return On Capital Employed is likely to grow to -0.1. As of 05/23/2024, Total Current Liabilities is likely to drop to about 63.5 M. In addition to that, Liabilities And Stockholders Equity is likely to drop to about 1.3 B

Technical Drivers

As of the 23rd of May, Crispr Therapeutics shows the Standard Deviation of 2.66, risk adjusted performance of (0.09), and Mean Deviation of 2.13. Crispr Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We are able to interpolate and collect thirteen technical drivers for Crispr Therapeutics AG, which can be compared to its peers. Please confirm Crispr Therapeutics coefficient of variation and maximum drawdown to decide if Crispr Therapeutics is priced correctly, providing market reflects its regular price of 56.8 per share. Given that Crispr Therapeutics has information ratio of (0.20), we suggest you to validate Crispr Therapeutics AG's prevailing market performance to make sure the company can sustain itself at a future point.

Crispr Therapeutics Price Movement Analysis

Crispr Therapeutics Predictive Daily Indicators

Crispr Therapeutics Corporate Filings

Crispr Therapeutics Forecast Models

Crispr Therapeutics' time-series forecasting models are one of many Crispr Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Crispr Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Crispr Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Crispr shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Crispr Therapeutics. By using and applying Crispr Stock analysis, traders can create a robust methodology for identifying Crispr entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Crispr analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Crispr analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Crispr Therapeutics AG stock analysis indicators help investors evaluate how Crispr Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Crispr Therapeutics shares will generate the highest return on investment. By understating and applying Crispr Therapeutics stock analysis, traders can identify Crispr Therapeutics position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crispr Therapeutics AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.

Is Crispr Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Crispr Therapeutics. If investors know Crispr will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Crispr Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Crispr Therapeutics is measured differently than its book value, which is the value of Crispr that is recorded on the company's balance sheet. Investors also form their own opinion of Crispr Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Crispr Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Crispr Therapeutics' market value can be influenced by many factors that don't directly affect Crispr Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Crispr Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Crispr Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Crispr Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.